Company History

1995 Exact Sciences is founded.
February 2001 Exact Sciences holds Initial Public Offering.
March 2008 American Cancer Society includes multi-target stool DNA testing in colorectal cancer screening guidelines.
March 2009 American College of Gastroenterology includes multi-target stool DNA testing in its colorectal cancer screening guidelines.
April 2009 Kevin Conroy is appointed President and Chief Executive Officer and Maneesh Arora is appointed Chief Financial Officer.
August 4, 2009 Graham Lidgard, PhD is appointed Chief Scientific Officer.
July 28, 2010 Poster presented at American Association for Clinical Chemistry (AACC) shows Exact Sciences methylation detection achieves 100% sensitivity and specificity in colorectal cancer tissue.
October 28, 2010 Results of Exact Sciences validation study is released at American Association for Cancer Research (AACR) meeting in Philadelphia.
July 2011 Exact Sciences begins enrollment for the DeeP-C Study, the company’s pivotal clinical trial for colorectal cancer.
November 11, 2011 Exact Sciences presents data from a second validation study at the Association for Molecular Pathology annual meeting in Dallas, Texas.
October 18, 2012 Poster presented at American Association for Cancer Research (AACR) Frontiers in Cancer Prevention meeting in Anaheim, California shows Exact Sciences, at a nominal specificity of 90%, achieves sensitivity of 98% in the detection of colorectal cancer and 83% in the detection of high-grade dysplasia, the majority of which progress to cancer.
November 15, 2012 Exact Sciences completes enrollment of DeeP-C clinical study, the largest privately funded study of its kind for colorectal cancer screening, enrolling more than 12,700 subjects.
December 7, 2012 Exact Sciences submits to the U.S. Food and Drug Administration the first module of the premarket approval application for its multi-target stool DNA colorectal cancer screening test.
April 18, 2013 Exact Sciences announces DeeP-C clinical study preliminary top-line results.
March 19, 2014 Results from the DeeP-C pivotal clinical study are published online in the New England Journal of Medicine.
March 27, 2014 The U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determines by a unanimous vote of 10 to zero that Exact Sciences demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard ®, the company's multi-target stool DNA (sDNA), non-invasive colorectal cancer screening test.
April 3, 2014 Results from the DeeP-C study are published in the New England Journal of Medicine’s April 2014 print issue.
August 11, 2014 The U.S. Food and Drug Administration (FDA) approves Cologuard. Exact Sciences also receives a proposed coverage memorandum from the Centers for Medicare and Medicaid Services (CMS). Cologuard is the first product to take part in the joint FDA and CMS parallel review pilot program in which both agencies simultaneously review medical devices.
October 9, 2014 The Centers for Medicare & Medicaid Services (CMS) issues its final National Coverage Determination (NCD) for Cologuard, making it the first and only Food and Drug Administration (FDA) approved multi-target stool DNA test for the detection of colorectal cancer and precancer covered by Medicare.
November 6, 2014 The American Cancer Society (ACS) guidelines include Cologuard in a recommended list of screening options for colorectal cancer.
February 6, 2015 Exact Sciences Corp. and Mayo Clinic announce a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.
June 15, 2016 United States Preventive Services Task Force (USPSTF) includes Cologuard in its final colorectal cancer screening recommendations on equal standing among the other included screening tests.
October 3, 2016 Cologuard included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. More than 90 percent of America's health plans measure quality based on HEDIS.
October 28, 2016 Cologuard wins Prix Galein Award for Best Medical Technology Product.
April 4, 2017 CMS includes Cologuard in updated Medicare Advantage Star Ratings.
June 23, 2017 Exact Sciences partners with professional golfer Jerry Kelly to promote colorectal cancer screening.
November 7, 2017 PGA Tour Champions and Exact Sciences announce Cologuard Classic as new title of annual Tucson professional golf tournament.
March 2, 2018 Exact Sciences hosts inaugural Cologuard Classic in Tucson, AZ.
August 22, 2018 Exact Sciences Corp. and Pfizer Inc. announce an agreement through 2021 to co-promote Cologuard
February 27, 2019 Exact Sciences announces two million people have screened for colorectal cancer using Cologuard
June 26, 2019 Exact Sciences opens its new 169,000 square foot clinical laboratory and warehouse in Madison.
July 17, 2019 Exact Sciences designated a Great Place to Work-Certified™ company in 2019
September 23, 2019 Exact Sciences announces U.S. Food and Drug Administration (FDA) approval of its noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older.
November 8, 2019 Exact Sciences and Genomic Health combine, creating leading global cancer diagnostics company

Leading the battle against cancer, together.

Exact Sciences and Genomic Health have teamed up to take on cancer, together. By combining our leading portfolio of products, we are continuing our relentless pursuit of earlier detection and smarter answers.

Read the official announcementLearn more About Us